Evidence map›Paper›PMID 36231256›Full record

SynthesisInternational journal of environmental research and public health2022

Antibiotic Resistance during COVID-19: A Systematic Review.

Hadi Jaber Al Sulayyim, Rohani Ismail, Abdullah Al Hamid, Noraini Abdul Ghafar

Abstract readSystematic Review
In one paragraph

Synthesis in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Antimicrobial resistance before and after the COVID-19 pandemic in Northern Brazil.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Impact of the COVID-19 Pandemic on Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025
    Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hadi Jaber Al SulayyimInterdisciplinary Health Unit, School of Health Science, Universiti Sains Malaysia (Health Campus), Kubang Kerian 11800, Kelantan, Malaysia.ORCID 0000-0002-0307-2777
Rohani IsmailInterdisciplinary Health Unit, School of Health Science, Universiti Sains Malaysia (Health Campus), Kubang Kerian 11800, Kelantan, Malaysia.
Abdullah Al HamidSaudi Ministry of Health, Najran 11134, Saudi Arabia.
Noraini Abdul GhafarBiomedicine Program, School of Health Science, Universiti Sains Malaysia (Health Campus), Kubang Kerian 11800, Kelantan, Malaysia.ORCID 0000-0001-7662-5339

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the public health issues faced worldwide is antibiotic resistance (AR). During the novel coronavirus (COVID-19) pandemic, AR has increased. Since some studies have stated AR has increased during the COVID-19 pandemic, and others have stated otherwise, this study aimed to explore this impact. Seven databases-PubMed, MEDLINE, EMBASE, Scopus, Cochrane, Web of Science, and CINAHL-were searched using related keywords to identify studies relevant to AR during COVID-19 published from December 2019 to May 2022, according to PRISMA guidelines. Twenty-three studies were included in this review, and the evidence showed that AR has increased during the COVID-19 pandemic. The most commonly reported resistant Gram-negative bacteria was

Indexed as

ColistinCOVID-19 Drug TreatmentAmpicillinAnti-Bacterial AgentsCiprofloxacinDrug Resistance, BacterialErythromycinEscherichia coliHumansMicrobial Sensitivity TestsPandemicsPseudomonas aeruginosaAmpicillinAnti-Bacterial AgentsCiprofloxacinColistinErythromycinantibiotic resistancecommon antibiotic-resistant bacteriaCOVID-19SARS-2

Identifiers

PMID36231256
PMCPMC9565540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.